News & numbers Development of Covid-19 therapeutics


To those outside the pharmaceutical industry, it may appear as though the development of vaccines stopped with the successful rollout of those from Pfizer, AstraZeneca and Moderna – or their equivalents distributed outside of the Western world. But in reality, R&D labs across the world are working on ways to improve on the current vaccine technology, as well as bring new treatments for Covid-19 to market. Industry advocacy group Biotechnology Innovation Organisation (BIO) has been tracking the development of products in all three categories by collating data from BioCentury and Biomedtracker.


860 Unique active compounds in development


Full Covid-19 pipeline analysis The ten countries leading therapy development: UK - 38


Canada - 49


403 Clinical compounds 457 Preclinical compounds


27% 237 Vaccines


31.5% 271 Antivirals


41.5% 352 Treatments


France - 24 India - 11 US - 424 Israel - 18 Switzerland - 28


An overview of Covid-19 drug development Antivirals


Late stage clinical (Phase III/IV)


Phase I Phase II Preclinical


0 20


33 36


63 37


23 28 128 148 35 124 185


50 100 150 200 250 300 350 400 450 Number of therapies


Numerous ways to target Covid-19: Top strategies COV2 antibody


anti-inflammatory (misc) Protein-based vax


anti-inflammatory (CRS indirect) antiviral (replication) rViral-based vax immune stimulator pulmonary function antiviral (cell entry) RNA-based vax antiviral (misc)


anti-inflammatory (CRS direct) Viral-based vax DNA-based vax vasodilation/bp anticoagulation Nanoparticle vax antiviral (immune cell) Cell-based vax


cardio/renal function anti-inflammatory (complement) 28 24 21


19 19


15


13 12


10 10


Source for all stats: BioCentury and Biomedtracker via BIO World Pharmaceutical Frontiers / www.worldpharmaceuticals.net 9 78 62


40 40 39


38


35 35


COV2 antibodies (plasma) antiparasitic


anti-inflammatory (steroid) antiviral (trafficking) antibacterial


neurological damage hormone regulation gastrointestinal function COV2 antibodies (mRNA-based) COV2 antibodies (DNA-based)


4 2


1 1 1 1 1


9 7 6


91 90


Antivirals Treatments Vaccines


108


New and repurposed treatment status by therapy type


New for C19 Redirected 71% 12% 97%


22% 64% 2%


Repurposed 7%


24% 1%


China - 51 Netherlands - 13 Germany - 39


Treatments


Vaccines


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53